ONCO.ST
Price:
$2.075
Market Cap:
$438.37M
Oncopeptides AB (publ), a biotech company, develops pharmaceuticals drugs for the treatment of cancer in the United States, Europe, and internationally. Its lead product candidate is melflufen, an anti-cancer peptide drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.[Read more]
Industry
Biotechnology
IPO Date
2017-02-22
Stock Exchange
STO
Ticker
ONCO.ST
According to Oncopeptides AB (publ)’s latest financial reports and current stock price. The company's current ROE is -280.43%. This represents a change of -289.49% compared to the average of 147.99% of the last 4 quarters.
The mean historical ROE of Oncopeptides AB (publ) over the last ten years is -61.14%. The current -280.43% ROE has changed 358.69% with respect to the historical average. Over the past ten years (40 quarters), ONCO.ST's ROE was at its highest in in the March 2024 quarter at 803.33%. The ROE was at its lowest in in the December 2016 quarter at -193.84%.
Average
-61.14%
Median
-204.62%
Minimum
-678.30%
Maximum
2.05%
Discovering the peaks and valleys of Oncopeptides AB (publ) ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 282.05%
Maximum Annual ROE = 2.05%
Minimum Annual Increase = -571.49%
Minimum Annual ROE = -678.30%
Year | ROE | Change |
---|---|---|
2023 | -438.73% | 282.05% |
2022 | -114.83% | -83.07% |
2021 | -678.30% | 145.38% |
2020 | -276.43% | 197.44% |
2019 | -92.94% | -30.02% |
2018 | -132.81% | 124.19% |
2017 | -59.24% | -86.37% |
2016 | -434.55% | -121.18% |
2015 | 2.05% | -571.49% |
The current ROE of Oncopeptides AB (publ) (ONCO.ST) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-410.62%
5-year avg
-320.25%
10-year avg
-61.14%
Oncopeptides AB (publ)’s ROE is less than Hansa Biopharma AB (publ) (242.32%), greater than BioArctic AB (publ) (-8.62%), greater than Calliditas Therapeutics AB (publ) (-210.18%), less than Sinch AB (publ) (0.56%), greater than Cantargia AB (publ) (-158.17%),
Company | ROE | Market cap |
---|---|---|
242.32% | $2.19B | |
-8.62% | $12.56B | |
-210.18% | $11.24B | |
0.56% | $20.13B | |
-158.17% | $547.39M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Oncopeptides AB (publ) using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Oncopeptides AB (publ) or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Oncopeptides AB (publ)'s ROE?
How is the ROE calculated for Oncopeptides AB (publ) (ONCO.ST)?
What is the highest ROE for Oncopeptides AB (publ) (ONCO.ST)?
What is the 3-year average ROE for Oncopeptides AB (publ) (ONCO.ST)?
What is the 5-year average ROE for Oncopeptides AB (publ) (ONCO.ST)?
How does the current ROE for Oncopeptides AB (publ) (ONCO.ST) compare to its historical average?